[1]潘逸聪,李楚齐,邵毅.靶向治疗视网膜疾病的研究进展[J].眼科新进展,2021,41(7):692-695.[doi:10.13389/j.cnki.rao.2021.0144]
 PAN Yicong,LI Chuqi,SHAO Yi.Research progress of targeted therapy for retinal diseases[J].Recent Advances in Ophthalmology,2021,41(7):692-695.[doi:10.13389/j.cnki.rao.2021.0144]
点击复制

靶向治疗视网膜疾病的研究进展/HTML
分享到:

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
41卷
期数:
2021年7期
页码:
692-695
栏目:
文献综述
出版日期:
2021-07-05

文章信息/Info

Title:
Research progress of targeted therapy for retinal diseases
作者:
潘逸聪李楚齐邵毅
330006 江西省南昌市, 南昌大学第一附属医院眼科
Author(s):
PAN YicongLI ChuqiSHAO Yi
Department of Ophthalmology, the First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China
关键词:
遗传性视网膜疾病腺相关病毒视网膜变性视网膜下基因治疗先天性黑矇"
Keywords:
inherited retinal diseases adeno-associated virus retinal degeneration subretinal gene therapy Leber’s congenital amaurosis
分类号:
R774
DOI:
10.13389/j.cnki.rao.2021.0144
文献标志码:
A
摘要:
作为一种非传统但十分新颖而精准的疗法,基因手段在多种遗传性视网膜疾病的诊治中代表了一种全新而可靠的希望,尤其是先天性黑矇与Stargardt病。近年来,随着临床应用技术和诊断水平的更新及提高,利用基因手段来诊治遗传性视网膜疾病成效颇丰。本文旨在概述测序技术和基因治疗在遗传性视网膜疾病中的作用和最新的研究进展,并对目前使用的主要三种靶向技术进行综述。
Abstract:
As a non-traditional but very novel and accurate method, genetic method represents a new and reliable hope in the diagnosis and treatment of most hereditary retinal diseases, especially for Leber’s congenital amaurosis and Stargardt disease. In recent years, with the update and improvement of clinical application technology and diagnosis level, the use of genetic means in the diagnosis and treatment of hereditary retinal diseases has achieved great results. The purpose of this paper is to summarize the role and latest research progress of sequencing and gene therapy in hereditary retinal diseases, and to review the three main targeting techniques used at present.

参考文献/References:

[1] 睢瑞芳,邹绚.遗传性视网膜疾病的基因诊断[J].眼科,2014,23(6):361-364.
SUI R F,ZOU X.Genetic diagnosis of hereditary retinal diseases [J].Ophthalmol CHN,2014,23(6):361-364.
[2] 王志玉,史爱云.视网膜挫伤兔模型的病理学观察[J].国际眼科杂志,2009,9(8):1469-1471.
WANG Z Y,SHI A Y.Pathological observation of rabbit model of retinal contusion [J].Int Eye Sci,2009,9(8):1469-1471.
[3] 夏阳,蔺云霞,徐玲.无黄斑病变近视患者黄斑区视网膜结构与视功能改变的相关性[J].眼科新进展,2020,40(5):457-460,465.
XIA Y,LIN Y X,XU L.Correlation between macular retinal structure and visual function in patients with myopia without maculopathy [J].Rec Adv Ophthalmol,2020,40(5):457-460,465.
[4] KUMARAN N,MOORE A T,WELEBER R G,MICHAELIDES M.Leber congenital amaurosis/early-onset severe retinal dystrophy:clinical features,molecular genetics and therapeutic interventions [J].Br J Ophthalmol,2017,101(9):1147-1154.
[5] MU W,LU H M,CHEN J,LI S,ELLIOTT A M.Sanger confirmation is required to achieve optimal sensitivity and specificity in next-generation sequencing panel testing [J].Mol Diagn,2016,18(6):923-932.
[6] ZICCARDI L,CORDEDDU V,GADDINI L,MATTEUCCI A,PARRAVANO M,MALCHIODI-ALBEDI F,et al.Gene therapy in retinal dystrophies [J].Int J Mol Sci,2019,20(22):5722.
[7] GáNDARA C,AFFLECK V,STOLL E A.Manufacture of third-generation lentivirus for preclinical use,with process development considerations for translation to good manufacturing practice [J].Hum Gene Ther Methods,2018,29(1):1-15.
[8] MADRAKHIMOV S B,YANG J Y,AHN D H,HAN J W,HA T H,PARK T K,et al .Peripapillary intravitreal injection improves AAV-mediated retinal transduction[J].Mol Ther Methods Clin Dev,2020,17:647-656.
[9] BARKER S E,BRODERICK C A,ROBBIE S J,DURAN Y,NATKUNARAJAH M,BUCH P,et al.Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice [J].J Gene Med,2009,11(6):486-497.
[10] VASCONCELOS H M Jr,LUJAN B J,PENNESI M E,YANG P,LAUER A K.Intraoperative optical coherence tomographic findings in patients undergoing subretinal gene therapy surgery [J].Int J Retina Vitreous,2020,6:13.
[11] JAYADEV C,DABIR S,VINEKAR A,SHAH U,VAID T,YADAV N K.Microscope-integrated optical coherence tomography:a new surgical tool in vitreoretinal surgery[J].Indian J Ophthalmol,2015,63(5):399-403.
[12] CIULLA T A,HUSSAIN R M,BERROCAL A M,NAGIEL A.Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases:a model for ocular gene therapy development [J].Expert Opin Biol Ther,2020,20(6):565-578.
[13] CAI S,THERATTIL A,VAJZOVIC L.Recent developments in pediatric retina [J].Curr Opin Ophthalmol,2020,31(3):155-160.
[14] PIERCE E A,BENNETT J.The status of RPE65 gene therapy trials:safety and efficacy [J].Cold Spring Harb Perspect Med,2015,5(9):a017285.
[15] 梁小芳,睢瑞芳,董方田.全色盲遗传学研究进展[J].中华实验眼科杂志,2015,33(8):764-767.
LIANG X F,SUI R F,DONG F T.Advances in genetics of total color blindness [J].Chin J Exp Ophthalmol,2015,33(8):764-767.
[16] PONTIKOS N,ARNO G,JURKUTE N,SCHIFF E,BA-ABBAD R,MAIKA S,et al.Genetic basis of inherited retinal disease in a molecularly characterized cohort of more than 3000 families from the United Kingdom [J].Ophthalmology,2020,127(10):1384-1394.
[17] BIRTEL J,HOLZ F G,HERRMANN P.Gene therapy approaches to a rare retinal disease:Choroideremia[J].Dtsch Arztebl Int,2020,117(3):30.
[18] TANNA P,STRAUSS R W,FUJINAMI K,MICHAELIDES M.Stargardt disease:clinical features,molecular genetics,animal models and therapeutic options[J].Br J Ophthalmol,2017,101(1):25-30.
[19] LENIS T L,HU J,NG S Y,JIANG Z,SARFARE S,LLOYD M,et al.Expression of ABCA4 in the retinal pigment epithelium and its implications for stargardt macular degeneration [J].Proc Natl Acad Sci USA,2018,115(47):e11120-e11127.
[20] PARKER M A,CHOI D,ERKER L R,PENNESI M E,YANG P,CHEGARNOV E N,et al.Test-retest variability of functional and structural parameters in patients with Stargardt disease participating in the SAR422459 gene therapy trial [J].Transl Vis Sci Technol,2016,5(5):10.
[21] VERBAKEL S K,VAN HUET R A C,BOON C J F,HOLLANDER A I D,COLLIN R W J,KLAVER C C W,et al.Non-syndromic retinitis pigmentosa [J].Prog Retin Eye Res,2018,66:157-186.
[22] JIANG P F,PENG J,OU C,YAO Z,TIAN Y.Experimental research progress of retinitis pigmentosa [J].Int Eye Sci,2020,20(6):970-973.
[23] RAO K N,LI L,ZHANG W,BRUSH R S,RAJALA R V,KHANNA H.Loss of human disease protein retinitis pigmentosa GTPase regulator (RPGR) differentially affects rod or cone-enriched retina [J].Hum Mol Genet,2016,25(7):1345-1356.
[24] LAVAIL M M,YASUMURA D,MATTHES M T,MATTHES M,YANG H,HAUSWIRTH W W,et al.Gene therapy for MERTK-associated retinal degenerations[J].Adv Exp Med Biol,2016,854:487-493.
[25] KUTLUER M,HUANG L,MARIGO V.Targeting molecular pathways for the treatment of inherited retinal degeneration[J].Neural Regen Res,2020,15(10):1784-1791.
[26] MATHUR P,YANG J.Usher syndrome:Hearing loss,retinal degeneration and associated abnormalities[J].Biochim Biophys Acta,2015,1852(3):406-420.
[27] WILLIAMS D S,LOPES V S.The many different cellular functions of MYO7A in the retina[J].Biochem Soc Trans,2011,39(5):1207-1210.
[28] MOLDAY R S,KELLNER U,WEBER B H.X-linked juvenile retinoschisis:clinical diagnosis,genetic analysis,and molecular mechanisms [J].Prog Retin Eye Res,2012,31(3):195-212.
[29] VIJAYASARATHY C,SUI R,ZENG Y,ZENG Y,YANG G X,XU F,et al.Molecular mechanisms leading to null-protein product from retinoschisin (RS1) signal-sequence mutants in X-linked retinoschisis (XLRS) disease [J].Hum Mutat,2010,31(11):1251-1260.
[30] MA Y,ZHANG L,HUANG X.Genome modification by CRISPR/Cas9 [J].FEBS ,2014,281(23):5186-5193.
[31] ZHANG J H,ADIKARAM P,PANDEY M,GENIS A,SIMONDS W F.Optimization of genome editing through CRISPR-Cas9 engineering [J].Bioengineered,2016,7(3):166-174.
[32] GARANTO A,CHUNG D C,DUIJKERS L,CORRAL-SERRANO J C,MESSCHAERT M,XIAO R,et al.In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery [J].Hum Mol Genet,2016,25(12):2552-2563.
[33] DONALDSON T N,JENNINGS K T,CHEREP L A,MCNEELA A M,DEPREUS F F,JODELKA F M,et al.Antisense oligonucleotide therapy rescues disruptions in organization of exploratory movements associated with Usher syndrome type 1C in mice [J].Behav Brain Res,2018,338:76-87.
[34] TRAPANI I,AURICCHIO A.Seeing the light after 25 years of retinal gene therapy [J].Trends Mol Med,2018,24(8):669-681.
[35] BERTSCH M,FLOYD M,KEHOE T,PFEIFER W,DRACK A V.The clinical evaluation of infantile nystagmus:what to do first and why?[J].Ophthalmic Genet,2017,38(1):22-33.

相似文献/References:

[1]丁芝祥 彭燕一 邱梅园 张玉明 曾新生.腺相关病毒介导HSV-tk/GCV 系统对晶状体上皮细胞的旁观者效应及机制[J].眼科新进展,2012,32(8):000.
[2]彭广华,王少军,杜璐.CRISPR/Cas9系统在视网膜发育与遗传性视网膜疾病研究中的应用[J].眼科新进展,2017,37(10):901.[doi:10.13389/j.cnki.rao.2017.0229]
 PENG Guang-Hua,WANG Shao-Jun,DU Lu.Application of CRISPR/Cas 9 system for the research of retinal development and inherited retinal diseases[J].Recent Advances in Ophthalmology,2017,37(7):901.[doi:10.13389/j.cnki.rao.2017.0229]
[3]鲍庆东,刘太祥,罗鑫,等.腺相关病毒介导的增强型绿色荧光蛋白基因转染豚鼠巩膜成纤维细胞的实验研究[J].眼科新进展,2020,40(11):1029.[doi:10.13389/j.cnki.rao.2020.0230]
 BAO Qingdong,LIU Taixiang,LUO Xin,et al.Expression of enhanced green fluorescent protein gene in guinea pig fibroblasts mediated by adeno-associated virus[J].Recent Advances in Ophthalmology,2020,40(7):1029.[doi:10.13389/j.cnki.rao.2020.0230]
[4]张瑞雪,蒋文君,石永伟,等.玻璃体内注射腺相关病毒介导原纤维蛋白-2基因干扰对小鼠视网膜的影响[J].眼科新进展,2021,41(9):806.[doi:10.13389/j.cnki.rao.2021.0169]
 ZHANG Ruixue,JIANG Wenjun,SHI Yongwei,et al.Effect of intervening the fibrillin-2 gene via intravitreal injection of adeno-associated virus on mouse retina[J].Recent Advances in Ophthalmology,2021,41(7):806.[doi:10.13389/j.cnki.rao.2021.0169]

备注/Memo

备注/Memo:
中央引导地方科技发展资金(编号:20211ZDG02003);江西省重点研发项目(编号: 20181BBG70004、20203BBG73059)
更新日期/Last Update: 2021-07-05